Hernandez Sarah L, Fasnacht Kathleen S, Sheyner Inna, King Julie M, Stewart Jonathan T
J Pain Palliat Care Pharmacother. 2015;29(4):374-7. doi: 10.3109/15360288.2015.1101640.
Persistent or intractable hiccups are not uncommon at the end of life, occurring in approximately 4% to 9% of patients, and can cause considerable suffering, including difficulties in eating, drinking, and speaking, insomnia, pain, fatigue, and depression. In palliative practice, the etiology of hiccups is often either unknown or untreatable, and empirical pharmacologic treatment is the norm. Unfortunately, many of the agents reported as effective for hiccups can cause undesirable sedation. The authors describe a patient with end-stage vascular dementia and a 4-year history of idiopathic intractable hiccups who responded dramatically to amantadine, a nonsedating dopamine agonist. The role of dopamine in hiccups is somewhat ambiguous and likely not central to their cause or treatment. Amantadine may be a reasonable option for patients with distressing hiccups who cannot tolerate a sedating agent.
持续性或顽固性呃逆在生命终末期并不少见,约4%至9%的患者会出现,可导致相当大的痛苦,包括进食、饮水和说话困难、失眠、疼痛、疲劳和抑郁。在姑息治疗中,呃逆的病因往往不明或无法治疗,经验性药物治疗是常态。不幸的是,许多据报道对呃逆有效的药物会引起不良的镇静作用。作者描述了一名患有终末期血管性痴呆且有4年特发性顽固性呃逆病史的患者,该患者对一种非镇静性多巴胺激动剂金刚烷胺反应显著。多巴胺在呃逆中的作用有些模糊,可能对其病因或治疗并非关键。对于不能耐受镇静剂且呃逆令人痛苦的患者,金刚烷胺可能是一个合理的选择。